InVivo Therapeutics' CEO Scheduled to Appear on FOX Business Network's "Varney & Company"
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, today announced that CEO Frank Reynolds is scheduled to appear live in New York City on FOX Business Network's "Varney & Company" on Tuesday, April 30th at approximately 10:25am ET. "Varney & Company" is a program hosted by veteran business journalist Stuart Varney that airs weekdays from 9:20am to 11:00am ET, giving over two million viewers the 411 on Wall Street.
InVivo Therapeutics has pioneered a treatment that uses a biocompatible polymer-based scaffold to provide structural support to a damaged spinal cord in order to spare tissue from scarring while improving recovery and prognosis after traumatic SCI. On the show, Reynolds will discuss this first product, the upcoming pilot study, and the platform the Company has built for developing new treatment options for a range of neurotrauma conditions tapping a more than $23 billion market opportunity.
Recently, the U.S. Food and Drug Administration (FDA) granted two approvals to the Company, the first for Humanitarian Use Device (HUD) designation, which the Company believes will expedite the product's path to market, and the second to approve the Company to begin a first-in-man clinical trial of the technology.
Stuart Varney joined FOX Business Network (FBN) as an anchor in 2007 and is the host of "Varney & Co." He also serves as a business contributor and substitute host for FOX News Channel's (FNC) "Your World with Neil Cavuto." Since joining FNC's business team in 2004, Varney has contributed to the network's business programming including: "Your World with Neil Cavuto," "Bulls & Bears," "Cavuto on Business" and "Cashin' In." Prior to joining FNC, Varney served as the host of CNBC's "Wall Street Journal Editorial Board with Stuart Varney" and was a co-anchor of CNN's "Moneyline News Hour." Varney helped launch CNN's business news team in 1980 and hosted many of their financial programs including, "Your Money," "Business Day" and "Business Asia." His reporting and analysis of the stock market crash of 1987 helped earn CNN a Peabody Award for excellence in journalism. A graduate of the London School of Economics, Varney began his broadcast journalism career as a business anchor for KEMO-TV in San Francisco.
FOX Business Network is a national network that airs locally on channel 789.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed from traumatic spinal cord injuries. The company was founded in 2005 based on proprietary technology co-invented by Robert S. Langer, ScD, Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David F. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.
Safe Harbor Statement
Certain statements contained in this press release that are not historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities and Exchange Act of 1934, and the Company intends that such statements are subject to the safe harbor created thereby. These statements include, but are not limited to, those relating to the expected approval of the FDA to conduct human clinical trials for the Company's products, the expected commencement date of any approved human clinical trials, the expected size of the pilot study, the expectation that the scaffold product will be regulated under a HDE pathway, and the expected acceleration of commercialization of the Company's products resulting therefrom. These forward-looking statements are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to obtain FDA approval to conduct human clinical trials; whether the human clinical trials produce acceptable results; the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our Annual Report on Form 10-K for the year ended December 31, 2012 and subsequent filings with the SEC.
Forward-looking statements contained in this press release speak only as of the date of this release. Subsequent events or circumstances occurring after such date may render these statements incomplete or out of date. The Company undertakes no obligation and expressly disclaims any duty to update such statements.
InVivo Therapeutics Holdings Corp.
Brian Luque, (617) 863-5535
Director, Investor Relations
KEYWORDS: United States North America Massachusetts
The article InVivo Therapeutics' CEO Scheduled to Appear on FOX Business Network's "Varney & Company" originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.